SITE001-0034

SITE001 (USA) › SITE001-0034

SITE001-0034

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2025-10-07

enrolled

AEs

3

Serious

0

Dropout signal

+0.25

Luna — Maya Okonkwo

Consent

granted

Messages

4

Escalations

0 escalations

Mood (avg feeling)

ø 4.0

Meds adherence (7d)

0%

Adverse events

3

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 183); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-20 (study day 160); relationship: NOT RELATED

moderate assessed

Grade 1 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 76); relationship: not assessed

mild assessed

Data queries

1

Temperature 3.7 C is below the plausible minimum 34 C.

F.VS.TEMP (Temperature) open